Navigation Links
SUPERaseIn from Ambion

ProductsSUPERaseIn from Ambion
Company Ambion
Item SUPERaseIn
Price $92.00
Description SUPERaseIn RNase Inhibitor (patent pending) is a protein based inhibitor of nonhuman origin that noncovalently binds and inhibits the most common and troublesome RNases including RNase A, B, C, 1 and T1. SUPERaseIn can be used in any application where RNase contamination could be problematic. It is ideal for in vitro transcription and translation, cDNA synthesis, RT-PCR, and preparation of RNase-free antibodies. Because it inhibits a broader range of RNases than traditional RNase inhibitors, SUPERaseIn is the most effective RNase inhibitor available providing a higher level of protection against degradation.

The most widely used RNase inhibitor is placental ribonuclease inhibitor (RIP). SUPERaseIn is distinct from RIP in that it has a more robust interaction with RNases, does not release active RNases in the absence of DTT, and inhibits a broader range of RNases. While placental ribonuclease inhibitors are effective only against RNase A type enzymes, SUPERaseIn also inhibits RNase 1 and T1. SUPERaseIn does not interfere with other enzymes such as RNA polymerases, reverse transcriptase or Taq polymerase. Additionally, SUPERaseIn is active up to 65C and for a pH range of 5.5 to 8.5.

Info AmbionAmbion
2130 Woodward
Austin, TX 78744
USA

Call Ambion to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-512-795-4221
Customer Service: 512-651-0200
Fax Number: 512-651-0201
Web Site: http://www.ambion.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. SUPERaseIn from Ambion
2. Silencer siRNA Starter Kit from Ambion
3. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
4. mirVana™ miRNA Bioarray Essentials Kit from Ambion
5. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
6. siPORT NeoFX Transfection Agent 1 ml from Ambion
7. siPORT NeoFX Transfection Agent from Ambion
8. DNase I (RNase-free) (2 U/l) from Ambion
9. TURBO DNase (2 U/l) from Ambion
10. Guanylyltransferase (5 U/l) from Ambion
11. 96 well Magnetic-Ring Stand 1 each from Ambion
geminin, DNA replication inhibitor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
biotin-4-fluorescein...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products:
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... Symbios Technologies, Inc. , ... company has engaged in a collaborative research partnership with Colorado State University (CSU) ... of the Vice President for Research. This agreement is designed to further the ...
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... 5, 2016  Renova™ Therapeutics, a biotechnology company ... and other chronic diseases, announced that Catherine ... Chief Financial Officer (CFO), effective today. ... of experience in financial management for a variety ... companies. Most recently, Ms. Bovenizer was the Vice ...
Breaking Biology Technology: